Stifel Nicolaus Boosts Medexus Pharmaceuticals (TSE:MDP) Price Target to C$4.50

Medexus Pharmaceuticals (TSE:MDP) had its target price upped by Stifel Nicolaus from C$4.15 to C$4.50 in a report released on Tuesday morning,BayStreet.CA reports.

A number of other research firms have also weighed in on MDP. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a report on Wednesday, January 8th. Finally, Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Two investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Trading Up 5.2 %

Shares of TSE:MDP opened at C$4.47 on Tuesday. The stock has a 50 day moving average of C$2.88 and a 200 day moving average of C$2.59. The company has a market cap of C$109.65 million, a PE ratio of 89.40 and a beta of 1.96. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$4.50.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.